Search
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration has recently acknowledged on its official website the acceptance of Bayer's application for marketing authorization of its novel Class 1 drug, BAY 2927088 tablets (sevabertinib). This innovative medication is an orally administered, reversible tyrosine kinase inhibitor tailored for adult patients diagnosed with unresectable or metastatic non-small cell lung cancer (NSCLC) who have undergone systemic therapy and harbor HER2 activating mutations. Previously, both the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) have bestowed upon this drug the Breakthrough Therapy Designation. At present, the specific indications for this cutting-edge treatment have yet to be disclosed.
-
C114 Communication Network -
Communication Home
